Encore Pharmaceuticals' Scientific References 1995-2000

Cancer Research

Wechter, W. J., Leipold, D. D., Murray, Jr., E. D., Quiggle, D., McCracken, J. D., Barrios, R. S., and Greenberg, N. M. "E-7869 (R-flurbiprofen) Inhibits Progression of Prostate Cancer in the TRAMP Mouse" (2000) Cancer Res. 60, 2203-2208.

Wechter, W. J., Leipold, D. D., Quiggle D. D., McCracken, J. D., Murray, Jr., E. D. and Loughman, B. E. "R-Flurbiprofen, A Chemopreventive and Teatment of Cancer" (2000) Inflammopharmacology 8, 189-206.

Wechter, W. J., Murray, Jr., E. D., Kantoci, D., Quiggle D. D., Leipold, D. D., Gibson, K. M. and McCracken, J. D. "Treatment and Survival Study in the C57BL/6J-APCMin/+ (Min) Mouse with R-Flurbiprofen" (2000) Life Sciences 66, 745-753.

Loughman, B.E., Wechter, W. J., Quiggle D. D., Lilly, M., Ruckle, H.C., Gutierrez, I., McCracken, J. D., Murray, Jr., E. D., Benaksas, E.J., Leipold, D. D. and Gibson, K.M. "Phase I-IIa Escalating Dose Studies of E-7869 (R-Flurbiprofen) in Normal Subjects and Prostate Cancer Patients" (1999) NCI Workshop on Strategies for Developing New Clinical Trials for Prostate Cancer Chemoprevention.

Wechter, W. J., Leipold, D. D., Murray, Jr., E. D., Quiggle D. D., McCracken, J. D., Barrios, R.S. and Greenberg, N.M. "The Tramp Mouse Model of Prostate Cancer: Effectiveness of E-7869" (1999) NCI Workshop on Strategies for Developing New Clinical Trials for Prostate Cancer Chemoprevention.

Wechter, W. J., McCracken, J. D., Kantoci, D., Murray, Jr., E. D., Quiggle D. D., Leipold, D. D., Gibson, K. M., Mineyama, Y. and Liu, Y. "Mechanism of Enhancement of Intestinal Ulcerogenicity of S-Aryl Propionic Acids by their R-Enantiomers in the Rat" (1998) Dig. Dis. Sci., 43, 1264-1274.

Wechter, W. J., Kantoci, D., Murray, Jr., E. D., Quiggle D. D., Leipold, D. D., Gibson, K. M. and McCracken, J. D. "R-Flurbiprofen Chemoprevention and Treatment of Intestinal Adenomas in the APCMin/+ Mouse Model: Implications for Prophylaxis and Treatment of Colon Cancer" (1997) Cancer Res. 57, 4316-4324.

McCracken, J. D., Liu, Y., Chase, R. L., Kantoci, D., Murray, Jr., E. D., Quiggle, D. D., Mineyama, Y., and Wechter, W.J., "The Antiproliferative Effects of the Enantiomers of Flurbiprofen" (1996) J. Clin. Pharm. 36, 540-545.

Cardiovascular Research

Wechter, W. J. and Murray, Jr., E. D. "Has the Elusive "Natriuretic Factor" Been Discovered, and If So, Is It a Hormone?" (1998) Exp. Nephrol., 6, 488-490.

Murray, Jr., E. D., Wechter, W. J., Kantoci, D., Wang, WH., Pham, T. Quiggle, D. D., Gibson, K. M., Leipold, D., and Anner, B. M. "Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic g-Tocopherol Metabolite LLU-a" (1997) J. Pharmacol. Exp. Ther. 282, 657-662.

Kantoci, D., Wechter, W. J., Murray, Jr., E. D., DeWind S. A., Borchardt D., and Khan, S. I. "Endogenous Natriuretic Factors 6: The Stereochemistry of a Natriuretic g-Tocopherol Metabolite LLU-a" (1997) J. Pharmacol. Exp. Ther. 282, 648-656.

Kantoci, D., Murray, Jr., E. D., Quiggle, D. D., and Wechter, W. J., "Endogenous Natriuretic Factors 5: Synthesis and Biological Activity of a Natriuretic Metabolite of Diltiazem and Its Derivatives" (1996) J. Med. Chem. 39, 1196-1200.

Wechter, W. J., Kantoci, D., Murray, Jr., E. D., D'Amico, D. C., Jung, M. E. and Wang, WH., "A New Endogenous Natriuretic Factor: LLU-a" (1996) Proc. Natl. Acad. Sci. USA, 93, 6002-6007.

Benaksas, E. J., Murray, Jr., E. D. and Wechter, W. J., "Natriuretic Hormones II" (1995) Prog. Drug Res. 45, 245-288.

Murray, E. D., Jr., Kantoci, D., DeWind, S. A., Bigornia, A. E., Levine, B. H., King, Jr., J. G., D'Amico, D. C., Jung, M. E. and Wechter, W. J., "Endogenous Natriuretic Factors 3: Isolation and Characterization of Human Natriuretic Factors LLU-a, LLU-b1 and LLU-g" (1995) Life Sciences 57, 2145-2161.

 

Home | Corporate Profile | Intellectual Properites | Press Releases | Contact Us